Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer
This cost-effectiveness analysis indicates that adebrelimab plus chemotherapy as a first-line treatment for ES-SCLC was not cost-effective in China with a WTP of $40,343.68.Reducing the cost of adebrelimab promises to improve the cost-effectiveness of this treatment regimen.
Authors
- Huide Zhu
- Zhiwei Zheng (ORCID: https://orcid.org/0000-0002-7815-3221)
- Ling Fang (ORCID: https://orcid.org/0000-0002-3070-1022)
Institutions
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1371/journal.pone.0325171
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05